NEXI

NexImmune, Yale, and JDRF Extend Research Partnership for Type 1 Diabetes

Retrieved on: 
Tuesday, October 24, 2023
NEXI, Nanoparticle, T1D, Anti-CD3 monoclonal antibody, Research, JDRF, Partnership, Vaccine, Yale University

GAITHERSBURG, Md., Oct. 24, 2023 (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI) announces the extension of the research partnership between NexImmune, Yale and JDRF to explore the use of NexImmune’s AIM nanoparticles in combination with an anti-CD3 mAb to tolerize, deplete or modulate diabetes antigen-specific T cells.

Key Points: 
  • GAITHERSBURG, Md., Oct. 24, 2023 (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI) announces the extension of the research partnership between NexImmune, Yale and JDRF to explore the use of NexImmune’s AIM nanoparticles in combination with an anti-CD3 mAb to tolerize, deplete or modulate diabetes antigen-specific T cells.
  • The extension includes an additional $300,000 grant, funded by JDRF to Yale, as a part of its Cures research portfolio, which includes therapies for the prevention of type 1 diabetes (T1D).
  • Combining anti-CD3 treatment with NexImmune’s injectable therapy provides the opportunity to target and modulate T1D antigen-specific T cells and potentially maintain their non-responsiveness with the goal to extend benefit and induce tolerance.
  • NexImmune’s nanoparticles have the potential to further enhance the effect of anti-CD3 through modulation of the residual T1D specific T cells.

Northland Power Announces Financial Close of the 1.0 GW Hai Long Offshore Wind Project in Taiwan Financing and Date for Investor Presentation Conference Call

Retrieved on: 
Thursday, September 28, 2023
Nippon Export and Investment Insurance, URL, UKEF, UK Export Finance, Export credit agency, Export Finance Australia, JBIC, EFA, Government, Multilateralism, Wind, Nguyễn Hai Long, NPI, NTD, NEXI, Webcast, TSX, Export Development Canada, Bond credit rating, EDC, Renewable energy, Financial services

TORONTO, Sept. 28, 2023 (GLOBE NEWSWIRE) -- Northland Power Inc. (Northland) (TSX: NPI) today announced that its Hai Long offshore wind project (Hai Long or the project) in Taiwan has successfully met all conditions to close its 1171 billion New Taiwan Dollars long-term non-recourse green financing (equivalent of CAD 5 billion).

Key Points: 
  • TORONTO, Sept. 28, 2023 (GLOBE NEWSWIRE) -- Northland Power Inc. (Northland) (TSX: NPI) today announced that its Hai Long offshore wind project (Hai Long or the project) in Taiwan has successfully met all conditions to close its 1171 billion New Taiwan Dollars long-term non-recourse green financing (equivalent of CAD 5 billion).
  • Hai Long will play an important role in helping the Government of Taiwan achieve its renewable energy target of 15 GW of offshore wind to be constructed between 2026 and 2035.
  • Once operational, Hai Long will be one of the largest offshore wind facilities in Asia, and will provide enough clean energy to power more than one million Taiwanese households.
  • There were no other material changes to the financial metrics disclosed within the press release dated September 21, 2023.

NexImmune Reports Second Quarter 2023 Financial Results and Provides Business Updates

Retrieved on: 
Thursday, August 10, 2023
ACT, AAPC, Yale University, JDRF, Nanoparticle, Lupus, Partnership, RA, AIM, Cohort, NYU, Pancreas, Bone marrow, HCT, GAAP, Infection, SLE, Research, Multiple sclerosis, Immunotherapy, Immunological memory, MS, ASCO, AML, Patient, Melanoma, Blood, NEXI, Vitiligo, FDA, IND, NIH, EBV, Autoimmunity, Rheumatoid arthritis, Disease, Vaccine, Pharmaceutical industry, T1D

We believe that the ability to bypass the host dendritic cell and directly engage T cells in the body provides the potential for greater specific T cell responses.

Key Points: 
  • We believe that the ability to bypass the host dendritic cell and directly engage T cells in the body provides the potential for greater specific T cell responses.
  • Cash and cash equivalents for the Company as of June 30, 2023 were $16.3 million compared to $34.6 million at December 31, 2022.
  • Based upon current operating plans, NexImmune expects that its existing cash and cash equivalents will enable the Company to fund its operating and capital expenditure requirements into the fourth quarter of 2023.
  • Research and development expenses were $4.9 million in the second quarter of 2023, compared to $11.8 million for the same period in the prior year.

Asahi Kasei Joins the Japan Hydrogen Forum to Support Decarbonization in the U.S.

Retrieved on: 
Wednesday, July 12, 2023
Technology, Manufacturing, Environmental Issues, Other Energy, Other Technology, Other Manufacturing, Green Technology, Alternative Energy, Environment, Energy, Sustainability, Hydrogen, Nippon Export and Investment Insurance, Fukushima Hydrogen Energy Research Field, Japan External Trade Organization, NEDO, JETRO, Kasei, New Energy and Industrial Technology Development Organization, Multimedia, JOGMEC, NEXI, Growth, Transport, Metal, Pharmaceutical industry, Lithium

Asahi Kasei (TOKYO:3407) announces that it has joined the Japan Hydrogen Forum (JH2F), which was established to support the decarbonization goals of U.S. federal, state, and local governments.

Key Points: 
  • Asahi Kasei (TOKYO:3407) announces that it has joined the Japan Hydrogen Forum (JH2F), which was established to support the decarbonization goals of U.S. federal, state, and local governments.
  • The company will advance activities as a member of the Hydrogen Production Committee, one of the five subcommittees of JH2F.
  • Asahi Kasei installed a large 10 MW-scale alkaline water electrolysis system at the Fukushima Hydrogen Energy Research Field (FH2R) as part of a NEDO project,1 and performed several trial operations2 since 2020.
  • Asahi Kasei will also build business in the U.S. for large-scale alkaline water electrolysis systems and their after-sales and technical services by leveraging the relationships gained across the value chain.

NexImmune Presents Initial Positive Data from the NEXI-001 Phase 1 Trial for Relapsed/Refractory Post Allo-HSCT AML at the American Society of Clinical Oncology 2023 Annual Meeting

Retrieved on: 
Monday, June 5, 2023
Ohio State University, Antigen, Nanoparticle, AIM, MI, Solar cycle 1, CRS, American Society of Clinical Oncology, Clinical trial, DLT, Cancer, Bone marrow, Transplant, BMT, Chimera, Immunotherapy, Associate, Pleural effusion, Trial of the century, Șaeș, Acute myeloid leukemia, ASCO, City of Hope National Medical Center, AML, City, Influenza, MD, Patient, ECOG, Blood, Internal medicine, NEXI, PET/CT, Periodic breathing, Countersurveillance, Poster, Neoplasm, Phenotype, Society, Memory, Safety, Salvage therapy, Vaccine, Pharmaceutical industry, Medical imaging, Hematology

GAITHERSBURG, Md., June 05, 2023 (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI), a biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells for liquid and solid malignancies, today announced results from its Phase 1/2 clinical trial of NEXI-001 in patients with relapsed/refractory acute myeloid leukemia (AML) post-allogeneic hemopoietic stem cell transplant (allo-HSCT). In this clinical trial to date, NEXI-001 is well tolerated with a favorable safety profile while eliciting an immune response to target antigens and a clinical effect in some patients. The data describing two patients from the dose escalation study of NEXI-001 are being presented in a poster session at the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting in Chicago on Monday, June 5 at 8 AM in Hall A.

Key Points: 
  • “We have seen a clinical response maintained for seven months, which is an additional update from the data reported in our poster.
  • These data have established the ability of our AIM nanoparticles to expand healthy, multi-antigen-specific T cells with anti-tumor activity.
  • The data also show these T cells persist and maintain their memory phenotype at the site of tumor.
  • These data indicating both immunologic and clinical dose responses and observed durability in the patient at the higher dose support further clinical study of NEXI-001.

NexImmune Announces Poster Presentation at the 2023 FOCIS Annual Meeting

Retrieved on: 
Monday, May 22, 2023
Sclerosis, AIM, Senior, National Center for Advancing Translational Sciences, Infection, Multiple sclerosis, Immunotherapy, MS, Federation, CD8, Publication, NEXI, Poster, Federation of Clinical Immunology Societies, NIH, EBV, Autoimmunity, Medicine, Disease, Vaccine

GAITHERSBURG, Md., May 22, 2023 (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI), a biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells in oncology, autoimmune and infectious diseases, today announced that it will be presenting a poster at the Federation of Clinical Immunology Societies (FOCIS) Annual Meeting, being held in Boston from June 20-23, 2023.

Key Points: 
  • GAITHERSBURG, Md., May 22, 2023 (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI), a biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells in oncology, autoimmune and infectious diseases, today announced that it will be presenting a poster at the Federation of Clinical Immunology Societies (FOCIS) Annual Meeting, being held in Boston from June 20-23, 2023.
  • This poster is a result of a collaboration between NexImmune and Dr. Steven Jacobsen at the NIH which is focused on two goals.
  • The second goal is to evaluate whether specific T cell defects can be circumvented as a potential development strategy to enable CD8+ specific killing of EBV+ cells that are believed to be a significant contributing factor to multiple sclerosis.
  • “We believe AIM products are uniquely positioned to deliver multi-antigen targeted approaches to address unmet need in these disease areas.”

NexImmune Reports First Quarter 2023 Financial Results and Provides Business Updates

Retrieved on: 
Monday, May 15, 2023
Sclerosis, AIM, Infection, Stroke, GAAP, Multiple sclerosis, Immunotherapy, Bangladesh Technical Education Board, ASCO, National Institute of Neurological Disorders and Stroke, DSM-IV codes, Pemphigus, Transplant, NEXI, BCMA, Vitiligo, Research, Autoimmunity, Vaccine, Pharmaceutical industry

“This is an exciting time for NexImmune, as we remain focused on progressing the development of novel approaches in the field of immunotherapy,” said Kristi Jones, NexImmune’s CEO.

Key Points: 
  • “This is an exciting time for NexImmune, as we remain focused on progressing the development of novel approaches in the field of immunotherapy,” said Kristi Jones, NexImmune’s CEO.
  • “Interest in antigen specific approaches for oncology, autoimmune disorders and infectious diseases has never been higher.
  • Based upon current operating plans, NexImmune expects that its existing cash and cash equivalents will enable the Company to fund its operating and capital expenditure requirements into the fourth quarter of 2023.
  • Research and development expenses were $6.1 million in the first quarter of 2023, compared to $10.4 million for the same period in the prior year.

NexImmune Announces Presentation of Phase 1/2 Clinical Data at the 2023 American Society of Clinical Oncology Annual Meeting

Retrieved on: 
Wednesday, April 26, 2023
Ohio State University, City of Hope National Medical Center, MI, American Society of Clinical Oncology, Immunotherapy, ASCO, City, MD, Internal medicine, NEXI, Society, Vaccine, Dentistry, Hematology

GAITHERSBURG, Md., April 26, 2023 (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI), a biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells for liquid and solid malignancies, today announced that clinical data from its Phase 1/2 dose escalation study of NEXI-001 will be presented in a poster session at the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting in Chicago, June 2 – June 6, 2023.

Key Points: 
  • GAITHERSBURG, Md., April 26, 2023 (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI), a biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells for liquid and solid malignancies, today announced that clinical data from its Phase 1/2 dose escalation study of NEXI-001 will be presented in a poster session at the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting in Chicago, June 2 – June 6, 2023.
  • (1)Hematology/Hematopoietic Cell Transplant, City of Hope National Medical Center, Duarte, CA, (2)Advent Health Blood and Marrow Transplant Program, Orlando, FL, (3)Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus Ohio, (4)Division of Oncology, Karmanos Cancer Center/Wayne State University, Detroit, MI, (5)NexImmune, Inc., Gaithersburg, MD

NexImmune Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Updates

Retrieved on: 
Tuesday, March 28, 2023
ACT, Nanoparticle, Executive, AIM, MOA, IO, GAAP, Research, Immunotherapy, Doctor of Philosophy, MD, Patient, BOD, Transplant, NEXI, R, BCMA, Pharmaceutical industry, Vaccine, Cryptocurrency

“The combined data from our clinical cell therapy programs and INJ preclinical experiments are consistent, and we believe validate the AIM nanoparticles MOA regardless of modality.

Key Points: 
  • “The combined data from our clinical cell therapy programs and INJ preclinical experiments are consistent, and we believe validate the AIM nanoparticles MOA regardless of modality.
  • The unique benefits of our “off-the-shelf” T cell targeted therapies include scalability and access to broader patient populations to address unmet needs.
  • Research and development expenses were $13.7 million in the fourth quarter ended December 31, 2022, compared to $12.0 million for the same period in the prior year.
  • General and administrative expenses were $3.5 million for the fourth quarter ended December 31, 2022, which represent effectively no change for the same period in the prior year.

NexImmune Announces Data Showing AIM ACT T cells Enhance the Response to Bispecific T cell Engager Therapy at the 2023 Tandem Meetings: Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR

Retrieved on: 
Thursday, February 16, 2023
ACT, TAA, Countersurveillance, NEXI, Immunotherapy, Lymphocyte function-associated antigen 1, AIM, CD4, Maintenance, Immunological memory, Patient, Bi-specific T-cell engager, Neoplasm, Hackensack University Medical Center, Discovery, Associate, Biting, Innovation, Transplant, Observation, CD8, Hackensack Meridian Health, Vaccine

AIM ACT T cells are non-engineered CTLs against 5 multiple myeloma antigen-peptide targets and include subtype populations (Tscm, Tcm, Tem) associated with anti-tumor activity and immunologic memory.

Key Points: 
  • AIM ACT T cells are non-engineered CTLs against 5 multiple myeloma antigen-peptide targets and include subtype populations (Tscm, Tcm, Tem) associated with anti-tumor activity and immunologic memory.
  • The abstract describes the ability of multi-TAA AIM ACT T cells to work synergistically with BiTE therapy, revealing several important advantages over endogenous TAA nonspecific CD8 T cells + BiTE.
  • The results show that BiTE potency, as measured by a reduction in tumor burden in vivo, is markedly increased in the presence of AIM T cells.
  • This observation strongly suggests that AIM ACT T cells provide immunosurveillance following the withdrawal of the BiTE, a distinct advantage over bulk CD8+ T cells, which should contribute to the maintenance of remission.